



Applications

- Treatment of Alzheimer’s disease
- Inhibit amyloid- β oligomers, oxidative stress, bio-metals and lipid rafts
- Potential to slow the progression of Alzheimer’s disease
- Diagnostic Imaging of beta-amyloid plaques

Advantages

- Multi-targeted approach to treat Alzheimer’s disease
- Studies indicate ligand crosses blood-brain-barrier

Inventors

[Shijun Zhang, Ph.D](#)


Contact

Magdalena K. Morgan, Ph.D.
 Director of Licensing
mkmorgan@vcu.edu
 Direct 804-827-6095

Alzheimer’s disease (AD) is estimated to afflict 4 million people in the US. The current treatments are limited to symptomatic treatment of cognitive function. The main challenge in AD treatment is its apparent multi-factorial nature. This necessitates the progression from single-target drug development to multi-target.

Technology Summary

Researchers at Virginia Commonwealth University have developed a series of novel compounds that are useful for the treatment and prevention of AD. These compounds target multiple risk factors involved in AD including amyloid- β oligomers ($A\beta O$) oxidative stress and bio-metals and cell membrane/lipid rafts. The multifunctional $A\beta$ oligomerization inhibitors (BMAOIs) strategy targeting CM/LR and other factors involved in the etiology of AD might be an ideal approach to overcome the limits of traditional single-target based approach.



Technology Status

Patent issued: U.S. rights are available – 9,260,473

Please see journal article- Lenhart *et al.* J. Med. Chem. 2010, 53, 6198–6209.

This technology is available for licensing to industry for further development and commercialization.